Skip to main content

Decision Pathway Developed for Diagnosing, Managing Myocarditis

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 17, 2024.

via HealthDay

TUESDAY, Dec. 17, 2024 -- In a 2024 guidance document issued by the American College of Cardiology and published online Dec. 10 in the Journal of the American College of Cardiology, recommendations are presented for the diagnosis and management of myocarditis.

Mark H. Drazner, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues present an expert consensus decision pathway for diagnosing and managing acute myocarditis in adult patients, reflecting recent advancements in clinical practice.

The authors note that clinicians should be aware of the three classic presentations of myocarditis: chest pain, heart failure/shock, and/or symptoms related to arrhythmia. High-sensitivity cardiac troponin (hs-cTn) is a common diagnostic test for suspected myocarditis, but some patients with myocarditis do not have elevated hs-cTn. Pivotal tests for diagnosis of myocarditis include cardiac magnetic resonance imaging and endomyocardial biopsy. A novel four-stage classification of myocarditis is suggested: Stage A relates to having or being exposed to risk factors; stage B to asymptomatic patients with evidence of myocardial inflammation; stage C to symptomatic myocarditis; and stage D to advanced myocarditis. The trajectories of the four stages need to be defined, including their risk for progression to chronic heart failure. For patients with symptomatic myocarditis, risk stratification guides the decision to refer to an advanced heart failure center with a multidisciplinary team. For myocarditis patients, follow-up does not end after two to three weeks, even if symptoms resolve, but should include two cardiac imaging studies at an early interval after diagnosis and at six months.

"Once a patient is diagnosed, clinicians can then follow the next four steps in the care pathway, including triaging the patient, obtaining pivotal diagnostic tests, providing appropriate therapies, and then longitudinal follow-up," Drazner said in a statement.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Remote CBT-Based Therapy Yields Modest Improvements in Chronic Pain

MONDAY, July 28, 2025 -- Remote-scalable cognitive behavioral therapy (CBT)-based chronic pain (CP) treatments yield modest improvements in high-impact chronic pain compared with...

Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes

MONDAY, July 28, 2025 -- For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major adverse cardiovascular events is...

Physical Activity Steadily Declines From Young Adulthood to Middle Age

MONDAY, July 28, 2025 -- Moderate-to-vigorous physical activity (MVPA) decreases from young adulthood into middle age, with accelerated declines seen within two years prior to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.